PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|February 15, 2023
Bayer Names Bill Anderson as CEO
Author(s)Pharmaceutical Technology Editors
Bill Anderson, former CEO of Roche’s pharmaceutical division, will take over as CEO of Bayer on June 1, 2023.
Advertisement
Bayer AG announced on Feb. 8, 2023 that Bill Anderson will take over as CEO on June 1, 2023. Anderson, the former CEO of Roche’s pharmaceutical division, has also held senior leadership positions with Biogen and Genentech.
“We are very excited to welcome Bill Anderson as the new CEO of Bayer. Bill has an outstanding track record of building strong product pipelines and turning biotech breakthroughs into products,” said Norbert Winkeljohann, chairman, Supervisory Board, Bayer AG, in a company press release. “Beyond that, he is a truly transformational leader who creates a culture that propels innovation, boosts productivity and performance, and allows people to thrive.”
“Bayer is an innovative company that is already delivering tremendous benefits for the nutrition, health and environmental protection of the world,” said Anderson in the release. “I look forward to working with the people of Bayer to accelerate innovation, increase performance, advance sustainability and unleash the full potential of the company.”
In addition to this appointment, Anderson is also slated to join Bayer’s board of management on April 1, 2023. Current CEO Werner Baumann is expected to aid in the transition through the end of May 2023.
Source:
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
4
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
5